Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Investing Activities (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Cash from Investing Activities for 7 consecutive years, with -$91.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 1901.91% to -$91.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.2 million, a 47.97% decrease, with the full-year FY2024 number at $25.2 million, down 69.71% from a year prior.
  • Cash from Investing Activities was -$91.6 million for Q3 2025 at Whitehawk Therapeutics, down from -$28.8 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $115.5 million in Q1 2025 to a low of -$91.6 million in Q3 2025.
  • A 5-year average of -$242529.4 and a median of $3.6 million in 2023 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 183332.61% in 2022, then skyrocketed 71095.65% in 2023.
  • Whitehawk Therapeutics' Cash from Investing Activities stood at -$46000.0 in 2021, then plummeted by 183332.61% to -$84.4 million in 2022, then soared by 104.32% to $3.6 million in 2023, then surged by 259.91% to $13.1 million in 2024, then tumbled by 797.69% to -$91.6 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Cash from Investing Activities are -$91.6 million (Q3 2025), -$28.8 million (Q2 2025), and $115.5 million (Q1 2025).